MoneyWorks4Me

Lupin informs about press release

10 Jan 2024 Evaluate
Lupin has informed that it enclosed a Press release regarding launch of Varenicline Tablets, 0.5 mg and 1 mg, after having received approval from the US FDA. This may be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2140.25 -12.35 (-0.57%)
03-Sep-2026 13:28 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1920.60
Dr. Reddys Labs. 1156.90
Cipla 1396.00
Lupin 2140.25
Zydus Lifesciences 1136.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: